Scalper1 News
Johnson & Johnson (JNJ) on Tuesday delivered strong quarterly results, led by its hepatitis C drug Olysio. But J&J shares slid nearly 2% in afternoon trading on the stock market today, as the medical giant does not expect the growth rate to continue. J&J’s earnings, excluding one-time items, rose 12% over the year-earlier quarter to $1.66 a share, beating analysts’ consensus by 11 cents. Sales rose 9% to Scalper1 News
Scalper1 News